Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study was designed to test the safety and efficacy of up to 3 pancreatic alloislet
transplants in type 1 diabetic patients with hypoglycemia unawareness. 6 subjects were
transplanted under this protocol using anti-thymocyte globulin induction immunosuppression
and everolimus with cyclosporine maintenance immunosuppression.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Juvenile Diabetes Research Foundation National Institutes of Health (NIH) Novartis